![]() Published in 2015, this paper reported on two trials of andexanet. Phase 2 trials in healthy volunteers showed that andexanet reversed the anticoagulant effects of apixaban, rivaroxaban, edoxaban, and enoxaparin in a dose-dependent and rapid manner. As such, it acts as a decoy protein binding and inactivating factor Xa inhibitors with high affinity in so doing, it reverses their anticoagulant effects. Like the low-molecular-weight heparins enoxaparin, dalteparin, and tinzaparin-but in contrast to dabigatran, heparin, and warfarin-factor Xa inhibitors lack an FDA approved reversal agent.Īndexanet is a recombinant modified factor Xa protein that lacks the enzymatic activity of factor Xa. ![]() In healthy older adults, what is the efficacy and safety of andexanet for reversing the anticoagulant effects of the factor Xa inhibitors apixaban or rivaroxaban?Īndexanet effectively reverses the anticoagulant effects of factor Xa inhibitors apixaban and rivaroxaban within minutes of administration.Īpixaban, rivaroxaban, and edoxaban are factor Xa inhibitors approved in the US for the management of nonvalvular atrial fibrillation and venous thromboembolism. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |